Cargando…
Protocol of notable-HCC: a phase Ib study of neoadjuvant tislelizumab with stereotactic body radiotherapy in patients with resectable hepatocellular carcinoma
INTRODUCTION: Liver resection is the mainstay of curative-intent treatment for hepatocellular carcinoma (HCC), but the postoperative 5-year recurrence rate reaches 70%, and there are no adjuvant or neoadjuvant therapies recommended by major HCC guidelines that can reduce the risk of recurrence. In t...
Autores principales: | Zhang, Bo, Yue, Jinbo, Shi, Xuetao, Cui, Kai, Li, Lei, Zhang, Chengsheng, Sun, Pengfei, Zhong, Jingtao, Li, Zhongchao, Zhao, Lei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9486305/ https://www.ncbi.nlm.nih.gov/pubmed/36115673 http://dx.doi.org/10.1136/bmjopen-2022-060955 |
Ejemplares similares
-
Preoperative inflammatory markers of NLR and PLR as indicators of poor prognosis in resectable HCC
por: Wang, Dong, et al.
Publicado: (2019) -
Impact of multiple liver resections prior to salvage liver transplantation on survival in patients with recurrent HCC
por: Hu, Zhenhua, et al.
Publicado: (2015) -
Meditation and yoga for irritable bowel syndrome: study protocol for a randomised clinical trial (MY-IBS study)
por: D'Silva, Adrijana, et al.
Publicado: (2022) -
Acceptability and efficacy of the Zemedy app versus a relaxation training and meditation app for IBS: protocol for a randomised controlled trial
por: Hunt, Melissa G, et al.
Publicado: (2022) -
Changing epidemiology of cirrhosis from 2010 to 2019: results from the Global Burden Disease study 2019
por: Xiao, Shiyu, et al.
Publicado: (2023)